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Background/Introduction
Destination therapy (DT) with mechanical circulatory
support (MCS) for advanced-stage heart failure patients
is an alternative therapy when there is no option of
eventually providing the patient with heart transplanta-
tion. New generation magnetically levitated pumps
encourage a broader use of DT.
Aims/Objectives
Aim of this study was to analyze follow up complications
and survival after DT with MCS.
Method
13 consecutive patients at our hospital were included in
this study. Only adult patients with magnetically levi-
tated Heartware® LVADs were included in this study.
We analyzed the indication and outcome of LVAD des-
tination therapy assessing risk profile, INTERMACS
classification, complication rates, and survival after
LVAD implantation (cut-off 30/06/2014).
Results
Our data show preoperative values including age [67.1
y+5.0 y] and INTERMACS classification [range 2-4].
The indication for DT includes old age, compliance pro-
blems, and severe comorbidities. Outcome data demon-
strate a low 30-day mortality in elective DT patients (100%
survival). Mean follow up after permanent Heartware
implantation was in average 544 days (range, 160-1512).
1 year survival after DT with HeartWare was 83.3%. Most
frequent complications include bleeding and stroke (1 GI-
bleeding, 1 permanent stroke, 1 recovered from SAB,
1 sternal wound infection). Using Heartware as DT LVAD
lead to reduction of required INR and hereby reduction of
complication rate.
Discussion/Conclusion
Destination therapy with magnetically levitated HeartWare
LVAD is associated with lower in-hospital mortality com-
pared to heart transplant patients. Long-term survival
after destination therapy is possible. Especially new mag-
netically levitated pumps with lower INR required might
help to further reduce LVAD complications
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